Corneal Crosslinking is a gentle, safe and effective treatment for Keratoconus, Pellucid Marginal
Degeneration (a form of Keratoconus) and post-LASIK ectasia. These are all progressive thinning
disorders of the cornea – the clear outer surface of the eye – which can lead to vision loss and the need for corneal transplantation.
Corneal Crosslinking has been utilized worldwide since the 1990’s but has only recently become available in the US through a variety of clinical trials, all testing different methods to improve collagen formation and strength of the cornea. In our clinical trial, we are utilizing Riboflavin (B2) that does not require the removal of the surface of the cornea, as well as UV light that requires less exposure time. These lead to much shorter and more comfortable healing times. This treatment has long been considered the standard of care in Europe and elsewhere in North America. The combination of Riboflavin and UV light promote strengthening of the corneal fibers, shoring up weak spots that result from kerataconus.
Intacts for Keratoconus
Intacs are a minimally invasive corneal insert, used along with corneal crosslinking, to treat keratoconus. FDA-approved in 1999, Intacs are tiny, crescent-shaped pieces of a clear plastic polymer that are inserted into the cornea to reshape and stabilize the front surface of the eye. They offer an alternative to cornea transplants for some keratoconus sufferers.
Is Keratoconus Treatment Right For You?
Ideal candidates for Corneal Crosslinking and/or Intacs are those identified early in their diagnosis with keratoconus. We are able to treat children as young as 15 years old and adults up to age 50. Children with a family history of keratoconus should be screened as early as possible.